論文 - 詳細
| RRC ID | 42754 |
|---|---|
| 著者 | Jiang P, Watanabe H, Okada G, Ohtsubo K, Mouri H, Tsuchiyama T, Yao F, Sawabu N. |
| タイトル | Diagnostic utility of aberrant methylation of tissue factor pathway inhibitor 2 in pure pancreatic juice for pancreatic carcinoma. |
| ジャーナル | Cancer Sci |
| Abstract |
The tissue factor pathway inhibitor 2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor. Recently, the aberrant methylation of TFPI-2 was detected frequently in pancreatic carcinoma (PCa) tissues but not in normal pancreatic tissues. We analyzed the aberrant methylation of TFPI-2 in the pure pancreatic juice (PPJ) aspirated endoscopically from patients with various pancreatic diseases. Using the highly sensitive methylation-specific polymerase chain reaction (MSP) and quantitative MSP (Q-MSP) assay, we investigated the aberrant methylation of TFPI-2 in nine human PCa cell lines and in the PPJ from patients with PCa, intraductal papillary mucinous neoplasms (IPMN) and chronic pancreatitis (CP). The incidence of aberrant TFPI-2 methylation was seven (77.8%) of nine PCa cell lines by Q-MSP. In cell lines, the expression of TFPI-2 mRNA by quantitative reverse transcription-polymerase chain reaction showed an inverse correlation to the aberrant methylation of TFPI-2. The incidence of aberrant TFPI-2 methylation in the PPJ was 21 (58.3%) of 36 PCa patients, three (17.6%) of 17 IPMN and one (4.8%) of 21 CP by MSP assay. Using a suitable cut-off value of 2.5 according to the receiver operating characteristic curve, the incidence of aberrant TFPI-2 methylation in the PPJ by real-time MSP was 18 (62.1%) of 29 PCa patients, one (5.1%) of 17 IPMN and three (14.3%) of 21 CP, respectively. The incidence of quantitative TFPI-2 hypermethylation in the PPJ with PCa was significantly higher than that with IPMN (P < 0.001) or CP (P < 0.001). Moreover, the aberrant methylation rate of TFPI-2 in the PPJ was 100%, as observed (6/6) in the PCa patients with liver metastasis, and 86.7% (26/30) in stages IVa + IVb of PCa by Q-MSP assay. These results suggest that promoter methylation of TFPI-2 in the PPJ may be a useful marker in the diagnosis and progression of PCa using an endoscopically feasible approach. |
| 巻・号 | 97(11) |
| ページ | 1267-73 |
| 公開日 | 2006-11-1 |
| DOI | 10.1111/j.1349-7006.2006.00308.x |
| PII | CAS308 |
| PMID | 16965396 |
| MeSH | Adenocarcinoma, Mucinous / diagnosis Adenocarcinoma, Mucinous / genetics Aged Antimetabolites, Antineoplastic / pharmacology Azacitidine / pharmacology Carcinoma, Pancreatic Ductal / diagnosis Carcinoma, Pancreatic Ductal / genetics Carcinoma, Papillary / diagnosis Carcinoma, Papillary / genetics Cell Line, Tumor DNA Methylation* DNA, Neoplasm / genetics DNA, Neoplasm / metabolism Female Gene Expression Regulation, Neoplastic Glycoproteins / genetics* Humans Male Middle Aged Pancreatic Juice / metabolism* Pancreatic Neoplasms / diagnosis* Pancreatic Neoplasms / genetics* Pancreatitis, Chronic / genetics Pancreatitis, Chronic / pathology Polymerase Chain Reaction Promoter Regions, Genetic RNA, Neoplasm / genetics RNA, Neoplasm / metabolism Reverse Transcriptase Polymerase Chain Reaction |
| IF | 4.966 |
| 引用数 | 22 |
| WOS 分野 | ONCOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | MIA Paca2(RCB2094) |